|
Jun 24
|
Will AbbVie's Growing Oncology Portfolio Aid Top-line Growth?
|
|
Jun 24
|
Age-Related Vision Dysfunction Market Research 2025-2035 | Kodiak Sciences, Genentech, and AbbVie Drive Innovations Through Advanced, Sustainable Solutions
|
|
Jun 23
|
J&J's Drugs Get CHMP Recommendations for Blood Cancer Indications
|
|
Jun 21
|
Is AbbVie the Best Dividend Stock in Big Pharma Today?
|
|
Jun 20
|
LLY vs. ABBV: Which Pharma Powerhouse is the Better Bet?
|
|
Jun 19
|
AbbVie’s Phase III trial of atogepant for migraine meets primary goal
|
|
Jun 18
|
AbbVie (NYSE:ABBV) Announces Positive Phase 3 Results for Migraine Drug Atogepant
|
|
Jun 18
|
GSK Stock Rises Almost 22% in 6 Months: Time to Buy, Sell or Hold?
|
|
Jun 18
|
AbbVie Announces New Data Demonstrating Atogepant (QULIPTA® / AQUIPTA®) Achieves Superiority Across All Endpoints in Phase 3 Head-to-Head Study Compared to Topiramate for Migraine Prevention
|
|
Jun 18
|
Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?
|
|
Jun 17
|
Trump's big beautiful bill: What the pharma industry is watching
|
|
Jun 17
|
3 Dividend Growth Stocks To Buy and Hold Forever
|
|
Jun 17
|
AMD extends gains, solar stocks plummet, pharma stocks
|
|
Jun 17
|
AbbVie's Venclexta Misses Goal in Myelodysplastic Syndromes Study
|
|
Jun 17
|
RFK Jr. Plans Crackdown on Pharma Ads in Threat to $10 Billion Market
|
|
Jun 17
|
AbbVie says Phase 3 Verona trial of venetoclax/azacitidine did not meet endpoint
|
|
Jun 17
|
AbbVie (ABBV) Pipeline Bolstered as FDA Approves Mavyret Label Expansion for Hepatitis C
|
|
Jun 17
|
AbbVie, ADARx Pharmaceuticals Partner to Develop Next-Gen siRNA Therapeutics
|
|
Jun 16
|
Sector Update: Health Care Stocks Retreat Late Afternoon
|
|
Jun 16
|
EHA 2025: Genmab and AbbVie’s Epkinly outpaces BiTE rivals in r/r DLBCL trial
|